General information and education, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Always consult a SEBI-registered adviser.
1. At a Glance
For the quarter ended June 30, 2026, Transchem Limited reported Revenue from operations of ₹0.00 crore. That is not a rounding artefact or a missing cell — the line simply has a dash in it, and has had one for most of the past decade.
Other Income came in at ₹5.11 crore, the largest quarterly figure in the company’s recent record. Total expenses were ₹0.76 crore. Net Profit was ₹3.42 crore, against ₹0.99 crore in the June 2025 quarter — a quarterly profit variation of 245%, achieved by a company that sold nothing at all. Basic EPS was ₹2.79; diluted EPS was ₹0.57, and the gap between those two numbers is one of the more interesting things on the page.
Around this quietly profitable shell, a considerable amount happened. In June 2026 the company allotted 6.15 crore warrants at ₹75 each, gross potential ₹461.25 crore, against a market capitalisation of ₹395 crore. On August 17, 2026 it completed the purchase of a stockbroker for ₹25.91 crore in cash. On August 10, the board approved the quarter’s results and, in the same sitting, version 3.0 of its insider-trading code.
The company that spent thirty-odd years growing mushrooms now has a Whole Time Director, ten permanent employees as of March 2025, and a loan book.
2. Introduction
Transchem Limited was incorporated in Maharashtra in 1976 — the CIN, L66120MH1976PLC019327, wears its age openly — and for most of its listed life it grew and exported mushrooms. It operated a 100% Export Oriented Unit for mushroom cultivation and processing. The plant then stopped operating for several years following changes in the international horticulture market, which is a sentence corporate India writes when it means the mushrooms stopped selling.
The exit was total. The entire undertaking — land at Bebadohol and Urse villages in Maval, Pune, plus buildings, machinery and fixtures — was sold for ₹26 crore, with the sale deed registered on June 17, 2020. After that, as the filings note, manufacturing, capacity and export metrics ceased to be applicable. Few companies get to formally retire an entire vocabulary.
What followed was five years of a listed entity earning from inter-corporate deposits and treasury investments. FY21 net profit was ₹24.15 crore, most of it arriving alongside Other Income of ₹26.82 crore. FY22 through FY26 ran at ₹2.87 crore, ₹1.24 crore, ₹4.20 crore, ₹5.23 crore and ₹4.30 crore.
In October 2025, shareholders amended the main objects to cover securities, commodity and currency broking, margin financing, depository-participant services, investment research and advisory, portfolio services, fund management and financial technology platforms. That is a wide net for a company whose previous object clause involved a fungus. The commercial financial-services operations had not commenced by March 2026.
Then the funding. An EGM on December 20, 2025 approved an increase in authorised capital and up to 6.15 crore preferential warrants. BSE granted in-principle approval on May 21, 2026. Allotment followed on June 3, 2026, with 4.75 crore of those warrants going to Bakkt Opco Holdings LLC.
US
Now live
US Stocks terminal is live
13,000+ US tickers · EDGAR fundamentals · screener and filings feed — the same terminal, for American markets.
Explore →
3. Business Model: WTF Do They Even Do?
Presently: very little, extremely profitably.
Revenue from operations for Q1 FY27 was nil, and FY26 revenue was ₹0.00 crore. The FY26 revenue mix, as disclosed, was interest on inter-corporate deposits at 83% and profit on property sale at 17% — a mix that describes lending money and selling land, neither of which the P&L is willing to call sales. The business model, stated plainly, has been: hold cash, lend it to corporates, collect interest, book it as Other Income, pay tax, repeat. Cash and bank stood at ₹42.43 crore at March 2026, and Other Assets — the line item that absorbs everything a balance sheet would rather not itemise — at ₹85.74 crore of an ₹87.73 crore total.
The disclosed loan book of ICDs outstanding was ₹3,200 lakh at March 2025, against ₹6,500 lakh a year earlier. The investment portfolio was ₹203.57 lakh across nine holdings. Nine holdings, ten permanent employees — comfortably under one holding per person, which is a ratio most asset managers can only dream about.
The new model arrived on August 17, 2026, when Transchem completed the acquisition of 100% of Greshma Shares & Stocks Limited for ₹25.91 crore in cash, making it a wholly owned subsidiary after receiving stock-exchange, clearing-corporation, CDSL and SEBI approvals. GSSL is a member of NSE’s cash and derivatives segments and BSE’s cash segment, and a CDSL depository participant. It provides equity and derivatives trading, IPO and mutual-fund distribution, ETFs and packaged financial products through dealer terminals, web and mobile platforms.
GSSL’s turnover was ₹9.47 crore in FY24, ₹11.32 crore in FY25 and ₹5.98 crore in FY26, with net worth of ₹21.32 crore at March 2026. Customer numbers, active-client mix, broking volumes and geographical revenue contribution were not disclosed. Which
